AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00127673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
Study NCT00661063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine 150 mcg/g bid
Study NCT00661063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: bid - 12 weeks
Study NCT00661063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine + clonidine
Description: ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
Study NCT00661063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine gel 1%
Description: bid 12 weeks
Study NCT00003166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00118222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: porfimer sodium
Description: All patients receive porfimer sodium IV.
Study NCT01607099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compatibility
Description: Patients asses the compatibility of the bowel cleansing procedure
Study NCT02473913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle
Study NCT02473913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02371278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Leucine
Description: 5 g leucine with sucrose and maltodextrin
Study NCT02371278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 5 g glycine with sucrose and maltodextrin
Study NCT04456296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aveed Injectable Product
Description: Testosterone undecanoate administered by intramuscular injections.
Study NCT02582905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active comparators in appearance.
Study NCT04456296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortesta
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Study NCT04456296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Study NCT00067808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 10 mg/m\^2 by vein over 1 hour daily for 10 days
Study NCT02582905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
Study NCT02582905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
Study NCT02578524 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT03578900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeros
Study NCT03578900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric Acid based Mouthwash
Study NCT03791398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 1 ONC201 625mg
Description: ONC201 625mg + Nivolumab 240mg IV flat dose
Study NCT00067808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 by vein (IV) over 1 hour daily x 5 days
Study NCT00067808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 subcutaneous (SQ) daily x 5 days
Study NCT02984787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic total gastrectomy
Description: When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
Study NCT02984787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic total gastrectomy
Description: When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
Study NCT02278822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose oral liposomal glutathione supplementation
Description: Low dose oral liposomal glutathione supplementation
Study NCT02278822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose oral liposomal glutathione supplementation
Description: High dose oral liposomal glutathione supplementation
Study NCT03791398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 2 ONC201 500mg
Description: ONC201 500mg + Nivolumab 240mg IV flat dose
Study NCT00118222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: All patients receive porfimer sodium IV.
Study NCT01844908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study NCT04246099 — intervention group
Intervention type: OTHER
Intervention: Post-operative care
Description: Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients.
Study NCT00118222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
Study NCT03507868 — intervention group
Intervention type: PROCEDURE
Intervention: Nonsurgical periodontal therapy
Description: Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.
Study NCT01739205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM-D Intervention
Description: Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
Study NCT03088202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: E-learning lectures, group exercises, skills training
Study NCT03088202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized care pathways
Description: Pathways for systematic follow-up
Study NCT03088202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care
Description: Compulsory referral to palliative care at inclusion
Study NCT04064138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peritoneal block
Description: At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
Study NCT04064138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae plane block
Description: Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
Study NCT04064138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia
Study NCT04494386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Lining Stem Cells (ULSC)
Description: IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
Study NCT04494386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (carrier control)
Description: IV infusion of carrier control consisting of sterile saline for injection
Study NCT00663416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTx™-265: rhCG, then rEPO
Description: * rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Study NCT01489696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT01489696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: oral
Study NCT00654888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALK (automated lamellar keratectomy)
Description: ALK is performed with a microkeratome, to make a free cap.
Study NCT00654888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: mitomycin 0,02%, 30 seconds after ALK
Study NCT01933139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-visual presentation
Study NCT03932435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisrt period TWLO_C
Description: First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
Study NCT03932435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisrt period TWLO
Description: First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
Study NCT03932435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout period
Description: 7 days
Study NCT03932435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second period TWLO_C
Description: Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
Study NCT03932435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second period TWLO
Description: Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
Study NCT00663416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: * Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation
Study NCT02268916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: OT led counseling
Study NCT03791398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 3 ONC201 375mg
Description: ONC201 375mg + Nivolumab 240mg IV flat dose
Study NCT01089140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10mg/kg/hr
Description: Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
Study NCT01089140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 100 mg/kg/h infusion
Description: Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
Study NCT01089140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline placebo
Study NCT01823744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient supplementation
Study NCT01910519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine plus AS03 adjuvant
Description: Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart.
Study NCT01910519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine without adjuvant
Description: Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart.
Study NCT04307212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50% heart rate reserve (HRR) low intensity exercise
Description: Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
Study NCT04307212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75% HRR moderate intensity exercise
Description: Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
Study NCT02268916 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual education
Description: At the end of the study, will receive OT-led counseling
Study NCT04628247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spring gravity bar
Description: 1. contain two wooden board length (160 cm) and width (15 cm)~2. contain pair of spring at every end of board~3. two wooden board connect in the middle
Study NCT01607515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Impedance cardiography
Description: noninvasive measure of cardiac index by impedance cardiography.
Study NCT03585023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spontaneous miscarriage
Description: Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
Study NCT04307212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control no exercise
Description: Trained and untrained participants will have a no exercise control day
Study NCT02422277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LI-ESWT group
Description: The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week.
Study NCT02422277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PDE-5 inhibitors group
Description: The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
Study NCT02755389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0 L/min oxygen via conventional nasal cannulae
Description: Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
Study NCT02755389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 L/min oxygen via conventional nasal cannulae
Description: Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
Study NCT02755389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 L/min oxygen via high-flow nasal cannulae
Description: Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
Study NCT02699281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultra-micronized palmitoylethanolamide
Description: ultra-micronized palmitoylethanolamide 600 mg twice a day
Study NCT03585023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Voluntary pregnancy interruption
Description: Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
Study NCT02699281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: um-PEA like placebo twice a day
Study NCT00917046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training
Description: 3 weekly sessions of high-intensity interval training in 12 weeks
Study NCT00917046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate continuous training
Description: 3 weekly sessions of moderate continuous training for 12 weeks
Study NCT00917046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation of regular moderate exercise
Description: Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
Study NCT03586635 — intervention group
Intervention type: OTHER
Intervention: neurological exam
Description: Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application
Study NCT03295968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise/Ibuprofen
Description: HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
Study NCT04816500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic ischemic conditioning treatment instrument
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
Study NCT04816500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regular treatment
Description: Antiplatelet agents and statins administration, vascular risk factors control.
Study NCT01280565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 7.5 mg/kg/day
Study NCT01280565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: IV bolus at 1,000 mg/m2 once every 3 weeks
Study NCT00876811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individually quick frozen red raspberries
Description: Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.